NDAC’s Wood Departs FDA Committee; Joins Private Investment Firm
This article was originally published in The Tan Sheet
Executive Summary
Nonprescription Drugs Advisory Committee Chairman Alastair Wood, MD, will depart NDAC in May and take a position at New York-based private equity firm Symphony Capital, the company announced May 1
You may also be interested in...
‘Emotional’ NDACs Stymie OTC Switches – Former Chairman Wood
OTC industry stakeholders must prepare better for FDA Nonprescription Drug Advisory Committee meetings and argue against members’ “emotional” objections to switches based on retail price or loss of doctor-patient visits, says former NDAC chair Alistair Wood.
‘Emotional’ NDACs Stymie OTC Switches – Former Chairman Wood
OTC industry stakeholders must prepare better for FDA Nonprescription Drug Advisory Committee meetings and argue against members’ “emotional” objections to switches based on retail price or loss of doctor-patient visits, says former NDAC chair Alistair Wood.
‘Emotional’ NDACs Stymie OTC Switches – Former Chairman Wood
OTC industry stakeholders must prepare better for FDA Nonprescription Drug Advisory Committee meetings and argue against members’ “emotional” objections to switches based on retail price or loss of doctor-patient visits, says former NDAC chair Alistair Wood.